Home / Compare / Zepbound vs Wegovy
Zepbound vs Wegovy (2026): The Brand Head-to-Head, Settled by a Trial and Complicated by a Heart
The only head-to-head that matters answered the efficacy question: in SURMOUNT-5, Zepbound (tirzepatide) averaged 20.2% weight loss versus Wegovy's (semaglutide) 13.7% — a decisive gap. Wegovy's counterpunch is outcomes seniority: SELECT proved a 20% reduction in major cardiovascular events, giving semaglutide a labeled heart benefit tirzepatide's own outcomes trial hasn't yet matched, plus an oral form and the deepest coverage footprint. The sort: maximum loss → Zepbound; established cardiovascular disease → Wegovy first; coverage decides everything else — a covered drug at $25–100 beats the uncovered rival at any cash price.
The trial that settled efficacy — and its honest edges
SURMOUNT-5 put the two brands head-to-head in the same trial — the comparison every cross-trial argument had approximated — and tirzepatide won clearly: 20.2% versus 13.7% average loss, with the dual GLP-1/GIP mechanism the leading explanation for the gap (the molecule-level analysis goes deep). The edges worth keeping: averages hide spread, and a strong semaglutide responder loses nothing by staying; tolerability profiles overlap far more than they differ, with tirzepatide leaning constipation and semaglutide nausea; and per-point value math at brand prices runs close, since the efficacy leader's LillyDirect vials ($299–449) undercut much of Wegovy-injectable's self-pay territory anyway.
Wegovy's real counterarguments
Three are genuine. SELECT: a completed cardiovascular-outcomes trial showing 20% MACE reduction in patients with established heart disease and overweight — a labeled, proven benefit that makes Wegovy the guideline-favored start for exactly that population until tirzepatide's outcomes program reports. The oral form: oral Wegovy's flat ~$149 (full guide) gives the semaglutide side the cheapest brand price in the category and the needle-free lane Zepbound lacks. Coverage momentum: the Novo–Hims partnership, NovoCare's aggressive self-pay pricing, and the Medicare Bridge covering Wegovy in all forms (versus Zepbound KwikPen only) mean the 'weaker' drug is frequently the cheaper or only covered one — and the coverage column outranks the efficacy column whenever they conflict.
The sort, patient by patient
Maximum-loss priority, no cardiac history: Zepbound — the 6.5-point head-to-head gap is the whole case. Established cardiovascular disease: Wegovy first, on SELECT's proof; revisit when tirzepatide's outcomes data lands. Needle-refusers: the semaglutide side (oral Wegovy) or Foundayo — Zepbound has no pill. Medicare Bridge users: both qualify at $50; pick on the efficacy-versus-heart logic above, remembering Zepbound must be the KwikPen. Everyone with insurance: run both coverage checks before this comparison gets a vote — the formulary is the real referee, and the coverage map plus the PA playbook are how you argue with it. The switching corridor between the two runs both directions with a one-week handoff, so the choice is an opening move, not a marriage.
Related: the molecule head-to-head · the pill duel · switching protocols
Tolerability and the switch corridor, in practice
Beyond the efficacy and outcomes headlines, the lived differences are small but decision-relevant. Side-effect profiles overlap heavily; the leanings are real but modest — tirzepatide skews slightly constipation-side, semaglutide slightly nausea-side — and individual response swamps the averages, which is why a miserable experience on one is a legitimate reason to trial the other rather than to abandon the class. The switch corridor runs both directions on the same mechanics: a one-week handoff (start the new drug when the old dose was due), a restart at the destination drug's initiation dose rather than a mapped equivalent, and a fresh titration judged on its own calendar — the full protocol lives in the switching guide. Two switch-specific money notes: coverage, savings-card eligibility, and Bridge treatment all reset with the product (Wegovy-all-forms versus Zepbound-KwikPen-only being the Bridge's famous asymmetry), and self-pay switchers should re-run the ladder math, because the cheapest lane on one side (oral Wegovy's $149) has no mirror on the other.
Head-to-head FAQ
Which causes fewer side effects, Zepbound or Wegovy?
Their profiles overlap far more than they differ — tirzepatide leans slightly toward constipation, semaglutide toward nausea, and individual variation dominates. A rough ride on one is a reason to trial the other, not to quit the class.
Can I switch from Wegovy to Zepbound?
Yes — the standard corridor is a one-week handoff, restarting at Zepbound's 2.5 mg initiation dose and titrating fresh. Non-response to semaglutide doesn't predict non-response to tirzepatide.
Is Zepbound or Wegovy better for heart health?
Wegovy holds the proven card: SELECT showed a 20% reduction in major cardiovascular events in patients with established heart disease. Tirzepatide's own outcomes program hasn't reported, which is why cardiac history tilts the start toward Wegovy for now.